

GENOMES2PEOPLE NEWS

FEBRUARY 2019

What Is The Value Of Sequencing Genomes of Healthy People?

Cohorts Convene in Boston to Launch the PeopleSeq Consortium

The Personal Genome Sequencing Outcomes (PeopleSeq) Consortium officially kicked off their NIH-funded project in Boston in late January, bringing together a one-of-a-kind cohort of leading academic and industry collaborators.



The Consortium will conduct a longitudinal study of healthy adults by surveying those who plan to, or have already received, their own genome sequence information.

Led by Dr. Robert C. Green, Genomes2People Research Program Director, PeopleSeq aims to assess the value of predispositional genome sequencing (PPGS) by:

- 1) Determining if information obtained from PPGS is associated with beneficial health related outcomes
- 2) Evaluating the individual risk and associated costs with PPGS
- 3) Exploring the value of this sequencing from the perspective participants who receive unanticipated monogenic findings.

The kick-off meeting served as a way to bring all current and interested collaborators together to discuss research aims and develop plans for future recruitment.



For more information on joining the Consortium, visit our [website](#).



The PeopleSeq Consortium Meeting Attendees

Genomes2People

Baylor College of Medicine

Geisinger

GeneDx

Genome Medical

Genos/NantOmics

Harvard Personal Genome

HudsonAlpha

Illumina

Invitae

Mayo

OpenSNP

PerkinElmer

SoundRocket

University of Vermont

Veritas

Scientific Team:

Michael Linderman, PhD

Consultants:

Scott Roberts, PhD

Tshaka Cunningham, PhD

Luisel Ricks-Santi, PhD

James Lillard Jr., PhD, MBA

Kareem Washington, PhD

Altovise Ewing, PhD, MS, CGC

Anthony Johnson, MBA